{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:45:37Z","timestamp":1787222737616,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10637-017-0476-6","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T07:21:14Z","timestamp":1496215274000},"page":"842-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Valentine","family":"Heidelberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jouinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gu\u00e9gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mansuet-Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Fran\u00e7oise","family":"Avril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9lim","family":"Aractingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. doi:10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"476_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521\u20132532. doi:10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"476_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918. doi:10.1016\/S1470-2045(15)00083-2","journal-title":"Lancet Oncol"},{"key":"476_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384. doi:10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"key":"476_CR5","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/S1470-2045(15)00003-0","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Long GV, Schadendorf D, Flaherty K (2015) Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncol 16:e522\u2013e526. doi:10.1016\/S1470-2045(15)00003-0","journal-title":"Lancet Oncol"},{"key":"476_CR6","first-page":"3091","volume":"72","author":"MN Sirott","year":"1993","unstructured":"Sirott MN, Bajorin DF, Wong GY et al (1993) Prognostic factors in patients with metastatic malignant melanoma. A Multivariate Analysis Cancer 72:3091\u20133098","journal-title":"A Multivariate Analysis Cancer"},{"key":"476_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.1998.16.3.1103","volume":"16","author":"O Eton","year":"1998","unstructured":"Eton O, Legha SS, Moon TE et al (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol Off J Am Soc Clin Oncol 16:1103\u20131111. doi:10.1200\/jco.1998.16.3.1103","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol Off J Am Soc Clin Oncol 27:6199\u20136206. doi:10.1200\/JCO.2009.23.4799","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"476_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem S, Kasenda B, Spain L et al (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114:256\u2013261. doi:10.1038\/bjc.2015.467","journal-title":"Br J Cancer"},{"key":"476_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ejca.2013.12.015","volume":"50","author":"C Gaudy-Marqueste","year":"2014","unstructured":"Gaudy-Marqueste C, Archier E, Grob A et al (2014) Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. Eur J Cancer 50:1120\u20131124. doi:10.1016\/j.ejca.2013.12.015","journal-title":"Eur J Cancer"},{"key":"476_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/2326-6066.CIR-14-0115","volume":"2","author":"MA Swartz","year":"2014","unstructured":"Swartz MA (2014) Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res 2:701\u2013707. doi:10.1158\/2326-6066.CIR-14-0115","journal-title":"Cancer Immunol Res"},{"key":"476_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab Physiol Appliqu\u00e9e Nutr M\u00e9tabolisme 33:997\u20131006. doi:10.1139\/H08-075","journal-title":"Appl Physiol Nutr Metab Physiol Appliqu\u00e9e Nutr M\u00e9tabolisme"},{"key":"476_CR13","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 45:228\u2013247. doi:10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"476_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10555-006-8502-8","volume":"25","author":"SPL Leong","year":"2006","unstructured":"Leong SPL, Cady B, Jablons DM et al (2006) Clinical patterns of metastasis. Cancer Metastasis Rev 25:221\u2013232. doi:10.1007\/s10555-006-8502-8","journal-title":"Cancer Metastasis Rev"},{"key":"476_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jso.21816","volume":"103","author":"SPL Leong","year":"2011","unstructured":"Leong SPL, Gershenwald JE, Soong S et al (2011) Cutaneous melanoma: A model to study cancer metastasis. J Surg Oncol 103:538\u2013549. doi:10.1002\/jso.21816","journal-title":"J Surg Oncol"},{"key":"476_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-2133.2002.04867.x","volume":"147","author":"F Meier","year":"2002","unstructured":"Meier F, Will S, Ellwanger U et al (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147:62\u201370","journal-title":"Br J Dermatol"},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00000637-199201000-00013","volume":"28","author":"DS Reintgen","year":"1992","unstructured":"Reintgen DS, Cox C, Slingluff CL, Seigler HF (1992) Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 28:45\u201349","journal-title":"Ann Plast Surg"},{"key":"476_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/BF02574498","volume":"9","author":"PJ Allen","year":"2002","unstructured":"Allen PJ, Coit DG (2002) The surgical management of metastatic melanoma. Ann Surg Oncol 9:762\u2013770","journal-title":"Ann Surg Oncol"},{"key":"476_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00000658-199402000-00003","volume":"219","author":"CL Slingluff","year":"1994","unstructured":"Slingluff CL, Stidham KR, Ricci WM et al (1994) Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 219:120\u2013130","journal-title":"Ann Surg"},{"key":"476_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/CMR.0000000000000218","volume":"26","author":"H Seifert","year":"2016","unstructured":"Seifert H, Fisher R, Martin-Liberal J et al (2016) Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma Res 26:138\u2013144. doi:10.1097\/CMR.0000000000000218","journal-title":"Melanoma Res"},{"key":"476_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433\u2013440. doi:10.1001\/jamaoncol.2015.1184","journal-title":"JAMA Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0476-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:09:48Z","timestamp":1678511388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0476-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0476-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"assertion":[{"value":"9 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors have no conflict of interest to declare related to the work described in the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work has received no funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}